Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 26, 2021 06:45 ET | Source: Genmab A/S

Genmab Announces 2020 Net Sales of DARZALEX® (daratumumab)

Company Announcement Net sales of DARZALEX® in 2020 totaled USD 4,190 millionGenmab receives royalties on worldwide net sales from Janssen Biotech, Inc. Copenhagen, Denmark; January 26, 2021 –...
January 15, 2021 14:18 ET | Source: Genmab A/S

Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Company Announcement DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) approved by U.S. FDA as the first and only therapy for newly diagnosed Light-chain (AL) amyloidosisAccelerated approval of...
January 13, 2021 09:20 ET | Source: Genmab A/S

Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie

Company Announcement Genmab to receive USD 40 million milestone payment from AbbVieMilestone triggered by progress in Phase 3 study of epcoritamab in diffuse large B-cell lymphoma Copenhagen,...
January 06, 2021 10:16 ET | Source: Genmab A/S

Genmab to Present at the 39th Annual J.P. Morgan Healthcare Conference

Media Release Copenhagen, Denmark, January 6, 2021 Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 39th Annual J.P. Morgan...
January 04, 2021 20:26 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement Copenhagen, Denmark; January 5, 2021 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses...
January 04, 2021 14:00 ET | Source: Genmab A/S

Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Media Release COPENHAGEN, Denmark, Jan. 04, 2021 Initiation of a global phase 3 trial for tisotumab vedotin versus investigator’s choice chemotherapy in recurrent or metastatic cervical cancer ...
December 15, 2020 17:09 ET | Source: Genmab A/S

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement Copenhagen, Denmark; December 15, 2020 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses...
December 15, 2020 17:01 ET | Source: Genmab A/S

Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Company Announcement Copenhagen, Denmark; December 15, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that at a board meeting the board decided to grant 9,663 restricted stock units to members of...
December 03, 2020 11:41 ET | Source: Genmab A/S

Genmab Announces that Janssen has Submitted a Biologics License Application to U.S. FDA for Amivantamab in Non-small Cell Lung Cancer

Media Release Copenhagen, Denmark, December 3, 2020 Janssen submitted a BLA to U.S. FDA for amivantamab for patients with non-small cell lung cancer with epidermal growth factor receptor Exon 20...
November 24, 2020 10:40 ET | Source: Genmab A/S

Genmab Announces Enapotamab Vedotin Update

Company Announcement Genmab will not advance the development of enapotamab vedotinData from expansion cohorts did not meet stringent criteria for proof-of-conceptGenmab to prioritize development of...